The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion announced its participation in the upcoming BIOEurope2026 conference, aiming to connect with both partners and investors.
The company is seeking to advance its metabolic disease pipeline through strategic meetings and collaboration opportunities scheduled at the event. Interested parties have been invited to arrange one-on-one sessions. Details are being clarified.
Biomea Fusion is pursuing a novel diabetes therapy, with Dr. Alice Cheng recently highlighting the promise of icovamenib for beta cell restoration in prior statements. The company has also scheduled an oral presentation on its icovamenib clinical data at ATTD 2006, targeting advancements in diabetes innovation, according to earlier disclosures. These initiatives reflect Biomea’s ongoing focus on developing treatments for metabolic diseases.